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Structure  
Outlining 
(A: 
Anatomical) 
(V: 
Volumetric) 
(p: p-value)  
Dosimetric parameter (Range)  
Mean 
(Gy)  
V70 (%) V60 (%) V50 (%) 
Superior 
Pharyngeal 
Constrictor  
A 70.1-71.0 53.8-82.1 98.8-100 All 100 
V 55.2-70.2 2.5-60.8 37.7-100 71.4-100 
p 0.005  0.005 0.005 0.012 
Middle 
Pharyngeal 
Constrictor 
A 69.5-71.5 54.2-90.1 97.6-100 All 100 
V  62.5-71.0 19.8-74.7 55.6-100 94.5-100 
p 0.007  0.005 0.012 0.043 
Inferior 
Pharyngeal 
Constrictor  
A 45.2-64.3 0-27.3 2-77.2 26.9-91.9 
V 44.4-65.8 0-33.1 0-83.3 20.8-92.8 
p 0.028 0.866 0.093 0.017 
Supraglottic 
Larynx  
A 54.6-69.7 26.7-59.9 53.1-100 57.3-100 
V 51.6-68.7 1.4-50.1 19.0-97.6 52.1-100 
p 0.005  0.005 0.007 0.012 
Oral Cavity  
A 41.8-56.3 0.3-10.8 7.0-44.5 22.1-66.9 
V 24.5-53.3 0-10.8 0-41.5 0.8-57.3 
p 0.012  0.093 0.012 0.012 
  
Volume (cm3)  
CTV1 
A 142.7-427.3  
V 70.7-402.2  
p 0.005  
Table 1: Mean dose Gray and partial volume doses as % 
 
Conclusions: This planning study demonstrated that the 
method of outlining influences the dose to normal structures. 
In particular, the dose to swallowing structures was 
significantly higher with anatomical outlining. This variation 
in delineating targets for treatment should be considered 
when assessing the final outcomes of this study. 
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Purpose/Objective: evaluating the clinical outcome of 
radiation dose escalation to 18FDG PET/CT positive tumor 
sub volumes using the Simultaneous Integrated Boost (SIB) 
IMRT technique by means of Helical Tomotherapy (HT), in 
locally advanced Oropharyngeal cancer patients. 
Materials and Methods: 38 patients treated between 2005 
and 2013 who underwent HT for squamocellular 
oropharyngeal stage III-IVB cancer were evaluated. HT was 
delivered with the SIB technique at different dose levels: 
69Gy (2.3 Gy/day) to the PET-positive volume (GTV-PET), 66 
Gy (2.2 Gy/day) to the clinical target volume for tumor and 
metastatic nodal stations, 54 Gy (1.8 Gy/day) to the clinical 
negative neck region concomitantly, in 30 fractions. 
Concurrent chemotherapy was given to 31 patients (cisplatin 
75-100 mg/m²/21 days for 23 patients, cisplatin 30-40 
mg/m²/week for 6 patients and Cetuximab for 2 patients) 
Metabolic indexes of primary tumour, including metabolic 
tumour volume (MTV), metabolic tumour volume thresholds 
40%, 50%, 60% (MTV-T-40%, MTV-T-50%, MTV-T-60%) and mean 
standardized uptake value (SUVmeanT) were also considered. 
Results: The median follow-up was 28 months (range: 3-109); 
all patients completed the treatment as scheduled. 
Temporary treatment interruption due to acute toxicity, 
mainly mucosae, was observed in 8 patients. The 2.5-year 
Overall Cancer specific (OS), Local disease-free Tumor (LTC) 
Local disease-free Nodal (LNC) and distant metastasis-free 
(DMFS) survivals were 88%, 83%, 88% and 77% respectively. 
Multivariate Cox regression analyses revealed that GTV-PET 
and GTV-T-PET are predictors for OS with a best-cut-off value 
equal to 30.9 cc (p=0.022) and 22.4 cc (p=0.029) 
respectively, while MTV-T-40%, MTV-T-60% and SUVmeanT 
are predictors for OS with a best-cut-off value equal to 21.3 
(p<0.0001), 13.3 (p<0.0001) and 9.2 (p=0.01) respectively 
Conclusions: The use of SIB-HT with dose escalation to 
18FDG-PET positive tumor sub-volumes is a feasible 
technique even with concurrent chemotherapy. Very 
promising 2.5-year loco-regional disease control rate are 
obtained. The results of the present study suggest that GTV-
PET has a predictive value for the SIB-HT outcome. These 
findings may constitute the basis for more personalized 
treatments.  
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Purpose/Objective: Dose to the oral mucosa and its 
contribution to acute mucositis is a dose/volume/outcome 
relationships recommended for investigation. Higher Dmean 
and Dmax would be supposed to produce more severe toxicity 
as such as other surveys have suggested. The aim of this 
study is to evaluate how different oral cavity (OC) contours in 
head-and-neck patients influence on treatment planning and, 
secondary, on the expected toxicity in head-and-neck IMRT. 
Materials and Methods: We analyzed the dose delivered to 
the oral cavity as organ at risk (OAR) designing three 
different contours in the same advanced head-and-neck 
cancer patient. Treatment was designed according to 
international recommendations utilising Intensity Modulated 
Radiotherapy (IMRT) technique with 7 fields and dynamic 
multileaf collimator, delivering 70 Gy to the Planning 
Treatment Volume (PTV). The Monaco treatment planning 
system with Monte Carlo algorithm was used. The 
Quantitative Analysis of Normal Tissue Effects in the Clinic 
(QUANTEC) report has not well-defined which structures 
should be included in the OC as organ at risk (OAR) and has 
not determined the constraints to apply. For this reason we 
defined three different contours including different 
structures (Tab. 1). Anterior OC included painful mucosa that 
can have a significant negative impact on quality of life and 
swallowing. Extended OC included anterior OC and other 
structures that inevitably are close to the PTV. Inner OC was 
a middle volume that includes the structures inside the 
gingiva. Oral cavity Dmean, Dmax, V50Gy, V45Gy, V40Gy, 
